The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT–Medicare linked data
PurposeThis study aimed to determine the 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drug use.MethodsThis is a post-trial passive follow-up study of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-11-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1272385/full |
| _version_ | 1797595164965863424 |
|---|---|
| author | Xianglin L. Du Journey Martinez Jose-Miguel Yamal Lara M. Simpson Barry R. Davis |
| author_facet | Xianglin L. Du Journey Martinez Jose-Miguel Yamal Lara M. Simpson Barry R. Davis |
| author_sort | Xianglin L. Du |
| collection | DOAJ |
| description | PurposeThis study aimed to determine the 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drug use.MethodsThis is a post-trial passive follow-up study of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants between 1994 and 1998 that was conducted by linking their follow-up data with Medicare claims data until 2017 of subjects who were free of outcomes at baseline on 1 January 1999. The main outcomes were the occurrence of cancer (among n = 17,332), angioedema (among n = 17,340), insomnia (among n = 17,340), depression (among n = 17,330), and erectile dysfunction (among n = 7,444 men) over 18 years of follow-up.ResultsThe 18-year cumulative incidence rate of cancer other than non-melanoma skin cancer from Medicare inpatient claims was 23.9% for chlorthalidone, 23.4% for amlodipine, and 25.3% for lisinopril. There were no statistically significant differences in the 18-year risk of cancer, depression, and erectile dysfunction among the three drugs based on the adjusted hazard ratios. The adjusted 18-year risk of angioedema was elevated in those receiving lisinopril than in those receiving amlodipine (hazard ratio: 1.63, 95% CI: 1.14–2.33) or in those receiving chlorthalidone (1.33, 1.00–1.79), whereas the adjusted 18-year risk of insomnia was statistically significantly decreased in those receiving lisinopril than in those receiving amlodipine (0.90, 0.81–1.00).ConclusionsThe 18-year risk of angioedema was significantly higher in patients receiving lisinopril than in those receiving amlodipine or chlorthalidone; the risk of insomnia was significantly lower in patients receiving lisinopril than in those receiving amlodipine; and the risk of cancer, depression, and erectile dysfunction (in men) was not statistically significantly different among the three drug groups. |
| first_indexed | 2024-03-11T02:32:34Z |
| format | Article |
| id | doaj.art-4976e1bc27654f699c01291dc165f61b |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-03-11T02:32:34Z |
| publishDate | 2023-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-4976e1bc27654f699c01291dc165f61b2023-11-18T10:07:42ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-11-011010.3389/fcvm.2023.12723851272385The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT–Medicare linked dataXianglin L. Du0Journey Martinez1Jose-Miguel Yamal2Lara M. Simpson3Barry R. Davis4Department of Epidemiology, Human Genetics and Environmental Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, United StatesDepartment of Biostatistics and Data Science, Coordinating Center for Clinical Trials, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, United StatesDepartment of Biostatistics and Data Science, Coordinating Center for Clinical Trials, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, United StatesDepartment of Biostatistics and Data Science, Coordinating Center for Clinical Trials, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, United StatesDepartment of Biostatistics and Data Science, Coordinating Center for Clinical Trials, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, United StatesPurposeThis study aimed to determine the 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drug use.MethodsThis is a post-trial passive follow-up study of Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants between 1994 and 1998 that was conducted by linking their follow-up data with Medicare claims data until 2017 of subjects who were free of outcomes at baseline on 1 January 1999. The main outcomes were the occurrence of cancer (among n = 17,332), angioedema (among n = 17,340), insomnia (among n = 17,340), depression (among n = 17,330), and erectile dysfunction (among n = 7,444 men) over 18 years of follow-up.ResultsThe 18-year cumulative incidence rate of cancer other than non-melanoma skin cancer from Medicare inpatient claims was 23.9% for chlorthalidone, 23.4% for amlodipine, and 25.3% for lisinopril. There were no statistically significant differences in the 18-year risk of cancer, depression, and erectile dysfunction among the three drugs based on the adjusted hazard ratios. The adjusted 18-year risk of angioedema was elevated in those receiving lisinopril than in those receiving amlodipine (hazard ratio: 1.63, 95% CI: 1.14–2.33) or in those receiving chlorthalidone (1.33, 1.00–1.79), whereas the adjusted 18-year risk of insomnia was statistically significantly decreased in those receiving lisinopril than in those receiving amlodipine (0.90, 0.81–1.00).ConclusionsThe 18-year risk of angioedema was significantly higher in patients receiving lisinopril than in those receiving amlodipine or chlorthalidone; the risk of insomnia was significantly lower in patients receiving lisinopril than in those receiving amlodipine; and the risk of cancer, depression, and erectile dysfunction (in men) was not statistically significantly different among the three drug groups.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1272385/fullcancerangioedemaantihypertensive drugsALLHATMedicare claims data |
| spellingShingle | Xianglin L. Du Journey Martinez Jose-Miguel Yamal Lara M. Simpson Barry R. Davis The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT–Medicare linked data Frontiers in Cardiovascular Medicine cancer angioedema antihypertensive drugs ALLHAT Medicare claims data |
| title | The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT–Medicare linked data |
| title_full | The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT–Medicare linked data |
| title_fullStr | The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT–Medicare linked data |
| title_full_unstemmed | The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT–Medicare linked data |
| title_short | The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT–Medicare linked data |
| title_sort | 18 year risk of cancer angioedema insomnia depression and erectile dysfunction in association with antihypertensive drugs post trial analyses from allhat medicare linked data |
| topic | cancer angioedema antihypertensive drugs ALLHAT Medicare claims data |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1272385/full |
| work_keys_str_mv | AT xianglinldu the18yearriskofcancerangioedemainsomniadepressionanderectiledysfunctioninassociationwithantihypertensivedrugsposttrialanalysesfromallhatmedicarelinkeddata AT journeymartinez the18yearriskofcancerangioedemainsomniadepressionanderectiledysfunctioninassociationwithantihypertensivedrugsposttrialanalysesfromallhatmedicarelinkeddata AT josemiguelyamal the18yearriskofcancerangioedemainsomniadepressionanderectiledysfunctioninassociationwithantihypertensivedrugsposttrialanalysesfromallhatmedicarelinkeddata AT laramsimpson the18yearriskofcancerangioedemainsomniadepressionanderectiledysfunctioninassociationwithantihypertensivedrugsposttrialanalysesfromallhatmedicarelinkeddata AT barryrdavis the18yearriskofcancerangioedemainsomniadepressionanderectiledysfunctioninassociationwithantihypertensivedrugsposttrialanalysesfromallhatmedicarelinkeddata AT xianglinldu 18yearriskofcancerangioedemainsomniadepressionanderectiledysfunctioninassociationwithantihypertensivedrugsposttrialanalysesfromallhatmedicarelinkeddata AT journeymartinez 18yearriskofcancerangioedemainsomniadepressionanderectiledysfunctioninassociationwithantihypertensivedrugsposttrialanalysesfromallhatmedicarelinkeddata AT josemiguelyamal 18yearriskofcancerangioedemainsomniadepressionanderectiledysfunctioninassociationwithantihypertensivedrugsposttrialanalysesfromallhatmedicarelinkeddata AT laramsimpson 18yearriskofcancerangioedemainsomniadepressionanderectiledysfunctioninassociationwithantihypertensivedrugsposttrialanalysesfromallhatmedicarelinkeddata AT barryrdavis 18yearriskofcancerangioedemainsomniadepressionanderectiledysfunctioninassociationwithantihypertensivedrugsposttrialanalysesfromallhatmedicarelinkeddata |